PAR 12.7% 31.0¢ paradigm biopharmaceuticals limited..

research reports and media, page-2991

  1. 9,723 Posts.
    lightbulb Created with Sketch. 1234
    Yep.......$20B market cap is a number that resonates as it would just 2x peak sales (assuming low case 10% market share and non-DMOAD pricing)

    We'd all be paying a lot more per share if we had more certainty.


 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.